1. Tuning of CHO secretional machinery improve activity of secreted therapeutic sulfatase 150-fold.
- Author
-
Thalén NB, Barzadd MM, Lundqvist M, Rodhe J, Andersson M, Bidkhori G, Possner D, Su C, Nilsson J, Eisenhut P, Malm M, Karlsson A, Vestin J, Forsberg J, Nordling E, Mardinoglu A, Volk AL, Sandegren A, and Rockberg J
- Subjects
- Humans, Sulfatases genetics, Sulfatases metabolism
- Abstract
Rare diseases are, despite their name, collectively common and millions of people are affected daily of conditions where treatment often is unavailable. Sulfatases are a large family of activating enzymes related to several of these diseases. Heritable genetic variations in sulfatases may lead to impaired activity and a reduced macromolecular breakdown within the lysosome, with several severe and lethal conditions as a consequence. While therapeutic options are scarce, treatment for some sulfatase deficiencies by recombinant enzyme replacement are available. The recombinant production of such sulfatases suffers greatly from both low product activity and yield, further limiting accessibility for patient groups. To mitigate the low product activity, we have investigated cellular properties through computational evaluation of cultures with varying media conditions and comparison of two CHO clones with different levels of one active sulfatase variant. Transcriptome analysis identified 18 genes in secretory pathways correlating with increased sulfatase production. Experimental validation by upregulation of a set of three key genes improved the specific enzymatic activity at varying degree up to 150-fold in another sulfatase variant, broadcasting general production benefits. We also identified a correlation between product mRNA levels and sulfatase activity that generated an increase in sulfatase activity when expressed with a weaker promoter. Furthermore, we suggest that our proposed workflow for resolving bottlenecks in cellular machineries, to be useful for improvements of cell factories for other biologics as well., Competing Interests: Declaration of competing interest Johan Rockberg reports equipment, drugs, or supplies was provided by Swedish Orphan Biovitrum AB. Johanna Rodhe reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Monica Andersson reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Dominik Possner reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Chao Su reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Joakim Nilsson reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Jeanette Vestin reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Johan Forsberg reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Erik Nordling reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. Anna Sandegren reports a relationship with Swedish Orphan Biovitrum AB that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF